Protocols - Hemorio

EXPECTED
BENEFITS
INFORMED
CONSENT FORM
TREATMENT MONITORING:
BEFORE TREATMENT INITIATION
- Reduction of Pain Episode frequency, which can even, disappear.
- Increase of hemoglobin F production and slight increase of Hb concentration
- STA episodes reduced
- Number of hospitalization reduced
- Slowing down of organ chronic degeneration
- Number of blood transfusion reduced
It is mandatory that patient or it legal representative is aware of potential risks
and side effects related to drug use recommended in this protocol, or what has to
be formalized by signing informed consent form.
EVERY 2 WEEKS UNTIL REACH MAINTENANCE DOSE
AND AFTER EVERY 4 WEEKS
EVERY 4 WEEKS UNTIL REACH MAINTENANCE DOSE
AND AFTER EVERY 12 WEEKS
EVERY 7 WEEKS UNTIL REACH MAINTENANCE DOSE
AND AFTER EVERY 24 WEEKS
39
- complete red blood cell test
- reticulocyte
- serology (HIV and hepatitis)
- TGO, TGP, bilirubin
- creatinine, urea, clearence
- sodium
- uric acid
- complete red blood cell test
- reticulocyte
- eletropheresis
ptn
- TAP
- ferritine
- hemoglobin F
- cytogenetic
- β-HCG
- LDH
- TAP, TGO, TGP, creatinine, gamma GT, alkaline
phosphatase
- hemoglobin F;
- LDH